<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350489</url>
  </required_header>
  <id_info>
    <org_study_id>AP-1720</org_study_id>
    <nct_id>NCT04350489</nct_id>
  </id_info>
  <brief_title>IL-32 Isoforms Levels in GCF and Plasma of the Patients With Periodontitis</brief_title>
  <official_title>Increased Levels of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Gingival Crevicular Fluid and Plasma of the Patients With Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bulent Ecevit University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bulent Ecevit University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interleukin (IL)-32, which has been recently reported to be associated with periodontitis,
      has been suggested to have pleiotropic effect due to its 9 different isoforms. The aim of
      this study was to investigate the levels of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in
      gingival crevicular fluid (GCF) and plasma before and after nonsurgical periodontal treatment
      in patients with periodontitis (P).Twenty-seven P and 27 periodontally healthy controls (C)
      were recruited in this study. Periodontitis patients were performed nonsurgical periodontal
      treatment. GCF and plasma sampling and clinical periodontal parameters were evaluated before
      and 1 month after treatment. Enzyme‐linked immunosorbent assay was used to analyze the levels
      of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in GCF and plasma samples.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>IL-32 isoforms levels</measure>
    <time_frame>baseline</time_frame>
    <description>the levels of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in gingival crevicular fluid (GCF) and plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-32 isoforms levels</measure>
    <time_frame>1st month after treatment</time_frame>
    <description>the levels of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in gingival crevicular fluid (GCF) and plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation</measure>
    <time_frame>baseline and 1st month after treatment</time_frame>
    <description>the levels of IL-32α, IL-32β, IL-32γ, IL-32δ isoforms in gingival crevicular fluid (GCF) and plasma and clinical parameters</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">54</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Periodontally healthy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis</arm_group_label>
    <description>Patients with periodontitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-surgical periodontal treatment</intervention_name>
    <description>Conventional non-surgical periodontal treatment were performed</description>
    <arm_group_label>Periodontitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. group (Control): Periodontally and systemically healthy

          2. group: Systemically healthy and periodontitis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have at least 20 natural teeth, excluding third molars.

          -  Periodontitis patients had at least two non-adjacent sites per quadrant with probing
             depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival
             inflammation, and alveolar bone loss affecting &gt;30% of the teeth, as detected on
             clinical and radiographical examinations.

          -  Periodontally healthy control group had no sign of gingival inflammation, no PD &gt; 3mm
             and no evidence of attachment or bone loss

        Exclusion Criteria:

          -  History of systemic disease.

          -  Regular use of any drugs which can effect the immune system or inflammatory response
             in the 6 months preceding the start of the study.

          -  Periodontal treatment during last 6 months that could affect periodontal status.

          -  Smoking.

          -  History of radiotherapy or chemotherapy.

          -  Current pregnancy, lactation or menopause.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ordu University</name>
      <address>
        <city>Ordu</city>
        <zip>52100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>T.C. ORDU ÜNİVERSİTESİ</investigator_affiliation>
    <investigator_full_name>Figen Öngöz Dede</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

